Antidepressant Effects of Ketamine on Depression-like Behavior in Juvenile Mice after Neonatal Dexamethasone Exposure

Su-Xia Li1,2, Ji-Chun Zhang1, Jin Wu1, Kenji Hashimoto1
1Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan, 2National Institute on Drug Dependence, Peking University, Beijing, P.R. China

Objective: Pediatric depression is associated with significant functional impairment at school and at work. Recently, we reported on depression-like behavior in juvenile mice neonatally exposed to dexamethasone (DEX) as a potential animal model for pediatric depression. The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine has promoted rapid and long-lasting antidepressant effects in patients with treatment-resistant major depression. This study was conducted to examine whether ketamine had antidepressant effects in juvenile mice after neonatal DEX exposure.

Methods: A single dose (10 mg/kg) of ketamine or vehicle was injected into juvenile mice at days 29–32 after neonatal DEX (or saline) exposure (days 1–3). The sucrose preference test, tail suspension test, and forced swimming test were performed 24, 40, and 46 hours, respectively, after injection of ketamine.

Results: Ketamine (10 mg/kg) significantly improved depression-like behavior in DEX-treated juvenile mice.

Conclusion: This finding suggests that ketamine confers antidepressant effects in an animal model of pediatric depression.

KEY WORDS: Depression; Dexamethasone; Ketamine; NMDA receptors; Antidepressants.

INTRODUCTION

Pediatric depression, a common psychiatric disease diagnosed in childhood and adolescence, is associated with interpersonal difficulties later in life, early parenthood, impaired school performance, unemployment, and other mental and substance abuse disorders.1,2 Despite the significant burden imposed by depression in children and adolescents, research has yet to determine the precise neurobiology of this disease.

Glucocorticoids are adrenocorticosteroid hormones that are secreted at high levels in response to activation of the hypothalamic-pituitary-adrenal (HPA) as part of a physiological response to stress. Chronic stress has a significant impact on neuroplasticity in limbic brain areas and is thought to contribute to the pathophysiology of major depression.3,4 Stress increases the levels of circulating corticosteroids, which act through glucocorticoid receptors in the brain. Very recently, we reported that neonatal exposure to dexamethasone (DEX), a potent synthetic glucocorticoid receptor agonist, induced depression-like behavior in juvenile mice.5 Furthermore, we found that alterations in glutamatergic transmission via the N-methyl-D-aspartate (NMDA) receptor may precipitate the behavioral abnormalities exhibited by juvenile mice after neonatal DEX exposure and that NMDA receptor antagonists could ameliorate the behavioral abnormalities in these mice.5 Taken together, our findings suggested that the behavioral abnormalities seen in juvenile mice after neonatal DEX exposure may represent an animal model of pediatric depression.

Growing evidence suggests that the glutamatergic system plays key roles in the neurobiology and treatment of major depression.6-13 The NMDA receptor antagonist ketamine has been associated with rapid and robust antidepressant effects in patients with treatment-resistant major depression.14,15 These effects were not apparent until after the psychotomimetic effects of ketamine had disappeared.14,16 Furthermore, the clinical benefits of a single dose of ketamine may last as briefly as 1 or 2 days or as long as more than 2 weeks.16,17 At present, ketamine is one of the most attractive antidepressants in the fight
against treatment-resistant depression.\(^{16,18-20}\)

The purpose of this study was to determine whether ketamine could improve depression-like behavior in juvenile mice after neonatal DEX exposure.

**METHODS**

**Animals and Treatment**

Male and female ICR mice (9 weeks old) were purchased from SLC Japan (Hamamatsu, Shizuoka, Japan). The mice were housed in groups of three or five per cage under a controlled 12/12-hour light/dark cycle (lights on from 7:00 AM to 7:00 PM) at a room temperature of 23±1°C and humidity of 55±5%. Mice were given free access to water and food pellets. Experimental procedures were approved by the Animal Care and Use Committee of Chiba University.

The breeding procedure consisted of housing three or four females with one male for 14 days. At the end of this period, females were isolated and checked daily around the expected delivery day. The day of birth was considered day 0. DEX was dissolved in physiological saline. During DEX treatment procedures (between 10:00 and 12:00 hours), dams were separated from their nests for a limited period of time (3-5 minutes), and pups were transported to an adjacent room where they were injected intraperitoneally (i.p.) with DEX (Wako Pure Chemical Co., Tokyo, Japan) on neonatal day 1 (0.5 mg/kg body weight), day 2 (0.3 mg/kg), and day 3 (0.1 mg/kg), or with equal volumes (10 mL/kg) of sterile pyrogen-free saline (SAL) (Fig. 1).\(^5\) All pups in a nest received either DEX or SAL. At weaning, all female mice were discarded. Male mice were housed under the same conditions until all experiments were concluded.

Ketamine hydrochloride was prepared from ketamine hydrochloride (Ketalar\(^\text{®}\), Daiichi Sankyo Pharmaceutical Ltd., Tokyo, Japan) and dissolved in physiological saline. During postnatal days 29-32, mice were injected with ketamine (10 mg/kg, i.p.) 24 hours before the sucrose preference test (SPT), 40 hours before the tail suspension test (TST), and 46 hours before the forced swimming test (FST) (Fig. 1).

**Sucrose Preference Test (SPT)**

Mice were habituated to a 1% sucrose solution for 48 hours before the test day. Mice were deprived of water and food for the 4 hours from 13:00 PM to 17:00 PM, and this was followed by a 1-hour preference test with water and
1% sucrose delivered from identical bottles. The bottles containing water and sucrose were weighed before and after this period, and sucrose preference (%) was determined.

**Tail Suspension Test (TST)**

Mouse tails were wrapped with tape from base to tip, covering approximately 4/5 of the tail length, and the mice were then fixed upside down on a hook. The immobility time of each mouse was recorded during a 10-minute period. Mice were considered immobile only when they hung passively and completely motionless. The observer assessing immobility was blind to the mouse groups.

**Forced Swimming Test (FST)**

Mice were placed individually in a cylinder (diameter, 23 cm; height, 31 cm) containing 15 cm of water maintained at 23±1°C. The water was changed between testing sessions. Mice were placed in the water for 6 minutes and then returned to their home cages. During testing, mice were video recorded from above, and the duration of immobility was determined during the 6-minute test period using a stopwatch.

**Statistical Analysis**

Data are presented as means±standard errors of the mean. The results of the SPT, TST, and FST were analyzed using one-way ANOVA, followed by the post hoc Bonferroni/Dunn test. For all analyses, differences were considered significant when p-values were lower than 0.05. Data were analyzed using the Statistical Package for the Social Sciences ver. 13.0 for Windows (SPSS Inc., Chicago, IL, USA).

**RESULTS**

We first performed the SPT 24 hours after a single dose of ketamine. The ANOVA revealed a significant difference \( [F(2, 27)=6.481, p=0.005] \) among the three groups. Subsequent post hoc analysis showed that neonatal DEX treatment significantly decreased preference for the 1% sucrose solution compared with SAL, indicating that neonatal DEX exposure produced anhedonia in juvenile mice. A single dose of ketamine (10 mg/kg) significantly attenuated this decreased preference for 1% sucrose (Fig. 1A).

Next, we performed the TST and FST 40 and 46 hours, respectively, after a single administration of ketamine. The immobility time of DEX-treated juvenile mice in both the TST and FST was significantly attenuated after a single dose of ketamine (10 mg/kg) (Fig. 1B, 1C). The ANOVA identified significant differences (TST: \( F[2, 27]=9.14, p=0.001 \), FST: \( F[2, 31]=13.61, p<0.001 \)) among the three groups. Subsequent post hoc analysis found that the immobility time of DEX-treated mice was significantly longer than that of SAL-treated mice (Fig. 1B, 1C), indicating that neonatal DEX exposure induces depression-like behavior in juveniles.

**DISCUSSION**

In this study, we found that neonatal DEX exposure (days 1-3) caused depression-like behavior (i.e., decreased preference for consumption of 1% sucrose and increased immobility times in the TST and FST) in juvenile mice and that a single dose of ketamine produced a long-lasting antidepressant effect in these affected animals. It is noteworthy that ketamine-induced antidepressant effects could be detected at 46 hours after a single ketamine dose. To the best of our knowledge, this is the first report of antidepressant effects of ketamine in juvenile mice after neonatal DEX exposure, a new animal model of pediatric depression.

Very recently, we reported that neonatal DEX exposure caused depression-like behavior in juvenile mice, suggesting that this could represent a new animal model of pediatric depression.5) Furthermore, we found alterations in the levels of the amino acids, glutamate, glutamine, glycine, D-serine, and L-serine in mouse brains after neonatal DEX exposure.5) Therefore, it is likely that the altered glutamatergic transmission via the NMDA receptor induced by neonatal DEX exposure may precipitate depression-like behavior in juvenile mice, as these amino acids are associated with NMDA receptor neurotransmission.8)

The unpredictable chronic mild stress (CMS) model and social defeat model are widely used animal models of depression.21) They are based on stress exposure during brain development or adulthood. In contrast, our model was based solely on neonatal DEX exposure. It is also well known that the HPA axis is hyperactive in patients with major depression.22) We found higher levels of blood corticosterone in juveniles after neonatal DEX exposure, suggesting hyperactivity of the HPA system in these mice.5) Thus, neonatal DEX exposure is able to alter neuroendocrinological stress axis functioning in later life, and this exposure may lead to depression-like behavior during the juvenile stages of development. Thus, it is very feasible that our model can be used as an animal model of de-
pression in childhood and adolescence.

In rodents, the paradigm of unpredictable CMS produced anhedonia, the loss of interest in normally pleasurable and rewarding activities, a core symptom of depression. Recently, we found that a single dose of ketamine (10 mg/kg) produced long-lasting antidepressant effects (measured by the 1% SPT, TST, and FST) in CMS mice. Interestingly, after even a single dose, the ketamine-induced increase in sucrose intake persisted for 8 days. In this study, we found that ketamine could ameliorate anhedonia in juvenile mice after neonatal DEX exposure. Our findings provide further evidence of the rapid onset and long-lasting antidepressant effects of ketamine in this new animal model of pediatric depression.

In conclusion, neonatal DEX exposure causes depression-like behavior in juvenile mice, and a single dose of ketamine produces a rapid and enduring antidepressant effect in these animals. It is therefore likely that depression-like behavior induced by neonatal DEX exposure in juvenile mice may constitute a potential animal model of pediatric depression.

Acknowledgments

This study was supported by a grant from Grants-in-Aid for Scientific Research on Innovative Areas of The Ministry of Education, Culture, Sports, Science and Technology, Japan (to K.H., Grant number: 24116006). Dr. Su-xia Li was supported by JSPS Invitation Fellowship Program for Research in Japan (Long term).

REFERENCES

1. Fergusson DM, Woodward LJ. Mental health, educational, and social role outcomes of adolescents with depression. Arch Gen Psychiatry 2002;59:225-231.
2. Cheung AH, Kozloff N, Sacks D. Pediatric depression: an evidence-based update on treatment interventions. Curr Psychiatry Rep 2013;15:381.
3. McEwen BS. Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 2007;87:873-904.
4. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008;33:88-109.
5. Li SX, Fujita Y, Zhang JC, Ren Q, Ishima T, Wu J, et al. Role of the NMDA receptor in cognitive deficits, anxiety and depressive-like behavior in juvenile and adult mice after neonatal dexamethasone exposure. Neurobiol Dis 2014;62:124-134.
6. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 2004;9:984-997.
7. Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci 2009;30:563-569.
8. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry 2007;62:1310-1316.
9. Hashimoto K. Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 2009;61:105-123.
10. Hashimoto K. The role of glutamate on the action of antidepressants. Prog Neuropsychopharmacol Biol Psychiatry 2011;35:1558-1568.
11. Hashimoto K. Therapeutic implications for NMDA receptors in mood disorders. Expert Rev Neurother 2013;13:735-737.
12. Zarate C Jr, Machado-Vieira R, Henter I, Ibrahim L, Diazgranados N, Salvador G. Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry 2010;18:293-303.
13. Tokita K, Yanaji T, Hashimoto K. Roles of glutamate signaling in preclinical and/or mechanistic models of depression. Pharmacol Biochem Behav 2012;100:688-704.
14. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-354.
15. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006;63:856-864.
16. Krystal JH, Sanacora G, Duman RS. Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 2013;73:1133-1141.
17. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? Biol Psychiatry 2012;72:537-547.
18. Domino EF. Taming the ketamine tiger. 1965. Anesthesiology 2010;113:678-684.
19. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropsychopharmacology 2012;62:35-41.
20. Zunszain PA, Horowitz MA, Cattaneo A, Lupi MM, Pariente CM. Ketamine: synaptogenesis, immunomodulation and glycogen synthase kinase-3 as underlying mechanisms of its antidepressant properties. Mol Psychiatry 2013;18:1236-1241.
21. Nestler EJ, Gould E, Manji H, Buncan M, Duman RS, Gershenfeld HK, et al. Preclinical models: status of basic research in depression. Biol Psychiatry 2002;52:503-528.
22. Pariente CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391-404.
23. Willner P. Chronic mild stress (CMS) revisited: consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 2005;52:90-110.
24. Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J, et al. Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 2013;8:e56053.